Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria. This is an ASCO Meeting Abstract from the 2025 ...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results